vs
Genius Sports Ltd（GENI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Genius Sports Ltd的1.5倍（$772.1M vs $510.9M），Revvity净利率更高（12.7% vs -12.3%，领先25.1%），Revvity自由现金流更多（$161.8M vs $69.6M），过去两年Genius Sports Ltd的营收复合增速更高（129.2% vs 9.0%）
Genius Sports是一家体育数据与科技企业，为体育联盟、博彩机构及媒体公司提供数据管理、视频流媒体和赛事诚信服务，致力于帮助合作伙伴优化运营效率、丰富用户体验，保障体育赛事的公平透明与商业价值落地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GENI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$510.9M
净利率更高
RVTY
高出25.1%
-12.3%
自由现金流更多
RVTY
多$92.2M
$69.6M
两年增速更快
GENI
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $510.9M | $772.1M |
| 净利润 | $-63.0M | $98.4M |
| 毛利率 | 25.2% | — |
| 营业利润率 | -11.5% | 14.5% |
| 净利率 | -12.3% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GENIRVTY
| Q4 25 | $510.9M | $772.1M | ||
| Q3 25 | $335.4M | $698.9M | ||
| Q2 25 | $215.2M | $720.3M | ||
| Q1 25 | $119.7M | $664.8M | ||
| Q4 24 | $413.0M | $729.4M | ||
| Q3 24 | $285.8M | $684.0M | ||
| Q2 24 | $184.1M | $691.7M | ||
| Q1 24 | $97.2M | $649.9M |
净利润GENIRVTY
| Q4 25 | $-63.0M | $98.4M | ||
| Q3 25 | — | $46.7M | ||
| Q2 25 | $-47.3M | $53.9M | ||
| Q1 25 | $-25.5M | $42.2M | ||
| Q4 24 | $-85.5M | $94.6M | ||
| Q3 24 | $-47.1M | $94.4M | ||
| Q2 24 | $-35.5M | $55.4M | ||
| Q1 24 | $-25.2M | $26.0M |
毛利率GENIRVTY
| Q4 25 | 25.2% | — | ||
| Q3 25 | 24.2% | 53.6% | ||
| Q2 25 | 19.1% | 54.5% | ||
| Q1 25 | 10.7% | 56.5% | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 20.5% | 56.3% | ||
| Q2 24 | 18.6% | 55.7% | ||
| Q1 24 | 9.8% | 54.6% |
营业利润率GENIRVTY
| Q4 25 | -11.5% | 14.5% | ||
| Q3 25 | -15.3% | 11.7% | ||
| Q2 25 | -21.0% | 12.6% | ||
| Q1 25 | -20.3% | 10.9% | ||
| Q4 24 | -18.0% | 16.3% | ||
| Q3 24 | -13.9% | 14.3% | ||
| Q2 24 | -16.8% | 12.4% | ||
| Q1 24 | -23.7% | 6.8% |
净利率GENIRVTY
| Q4 25 | -12.3% | 12.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | -22.0% | 7.5% | ||
| Q1 25 | -21.3% | 6.4% | ||
| Q4 24 | -20.7% | 13.0% | ||
| Q3 24 | -16.5% | 13.8% | ||
| Q2 24 | -19.3% | 8.0% | ||
| Q1 24 | -25.9% | 4.0% |
每股收益（稀释后）GENIRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $280.6M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $724.5M | $7.3B |
| 总资产 | $1.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GENIRVTY
| Q4 25 | $280.6M | $919.9M | ||
| Q3 25 | $110.2M | $931.4M | ||
| Q2 25 | $110.2M | $991.8M | ||
| Q1 25 | $110.2M | $1.1B | ||
| Q4 24 | $100.3M | $1.2B | ||
| Q3 24 | $100.3M | $1.2B | ||
| Q2 24 | $100.3M | $2.0B | ||
| Q1 24 | $100.3M | $1.7B |
股东权益GENIRVTY
| Q4 25 | $724.5M | $7.3B | ||
| Q3 25 | $572.4M | $7.4B | ||
| Q2 25 | $572.4M | $7.6B | ||
| Q1 25 | $572.4M | $7.6B | ||
| Q4 24 | $573.0M | $7.7B | ||
| Q3 24 | $573.0M | $7.9B | ||
| Q2 24 | $573.0M | $7.9B | ||
| Q1 24 | $573.0M | $7.8B |
总资产GENIRVTY
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $792.3M | $12.1B | ||
| Q2 25 | $792.3M | $12.4B | ||
| Q1 25 | $792.3M | $12.4B | ||
| Q4 24 | $775.7M | $12.4B | ||
| Q3 24 | $775.7M | $12.8B | ||
| Q2 24 | $775.7M | $13.4B | ||
| Q1 24 | $775.7M | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $81.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $69.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 13.6% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $33.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GENIRVTY
| Q4 25 | $81.9M | $182.0M | ||
| Q3 25 | $-4.8M | $138.5M | ||
| Q2 25 | $-1.2M | $134.3M | ||
| Q1 25 | $-14.6M | $128.2M | ||
| Q4 24 | $14.9M | $174.2M | ||
| Q3 24 | $-9.2M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流GENIRVTY
| Q4 25 | $69.6M | $161.8M | ||
| Q3 25 | $-14.2M | $120.0M | ||
| Q2 25 | $-5.8M | $115.5M | ||
| Q1 25 | $-16.0M | $112.2M | ||
| Q4 24 | $11.3M | $149.8M | ||
| Q3 24 | $-11.6M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率GENIRVTY
| Q4 25 | 13.6% | 21.0% | ||
| Q3 25 | -4.2% | 17.2% | ||
| Q2 25 | -2.7% | 16.0% | ||
| Q1 25 | -13.4% | 16.9% | ||
| Q4 24 | 2.7% | 20.5% | ||
| Q3 24 | -4.1% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度GENIRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 2.1% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 0.9% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率GENIRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GENI
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
